Wintop healthcare fund

WINTOP HEALTHCARE FUND

DISCLAIMER

Anyinforma+oncontainedwithinthispresenta+onshouldnotbedeemedtocons+tuteinvestmentadviceandshouldnotberelieduponasthebasisforadecisiontoenterintoatransac+on,orasthebasisforanyfinancialorinvestmentdecision.Investorsshouldalwaysseekprofessionaladviceinregardtothesuitabilityofanyinvestment.WintopCapitalPte.Ltd.acceptsnoliabilityforanylossesorconsequen+allossincurredbyinvestorsac+nguponanyinforma+oncontainedwithinthispresenta+on.Thevalueofinvestmentsandtheincomearisingfromthem,candecreaseaswellasincrease,andarenotguaranteed,whichmeansthataninvestormaynotgetbackwhattheyinvested.Changesinexchangeratesmayalsocausean investmenttofluctuate invalue.Levelsof taxa+onsdependonan investor's individualcircumstancesandthevalueofanyapplicabletaxreliefs.

WINTOP CAPITAL: A MAS-REGISTERED FUND MANAGER

WINTOPHEALTHCARE

FUND

(PrivateLimitedCompany)

WINTOPCAPITALPTE.LTD.

(RegisteredFundManager)

FOUNDERSHeLiMin

LeongMunWai

EXECUTIVE SUMMARY

Insa6ableDemand BalancedStrategy SuperiorReturn

HighMission CoreCompetencies

Insa+abledemandformoreandbeMerhealthcareproductsandservicesinAsiawhosepopula+onisincreasinglyaffluentandrapidlyageingatthesame+me.Thereisalsoapoli+calandsocialurgencyinmostAsiancountriestoprovideatleastaminimumlevelofhealthcarecoveragetotheirci+zens.

WintopHealthcareFund(WHF)seektoinvestininvesteeswhocontributetothecrea+onofamoreefficientandeffec+vehealthcaresystemwithagreateremphasisonpreven+onandwell-beingtoimprovegeneralhealthandqualityoflife.

WHFsinvestmentstrategyistohaveabalancedporTolioofinvestments40%intechnologyandR&Ddrivencompaniesand60%inopera+nghealthcareen++esthatarealreadygenera+ngacashflow.

Wintopsinvestmentteampossessesthreecorecompetenciesdomainknowledge,China/Japanconnec+onandcapitalmarketexperiencewhichenablesittofindthoseinvesteesandgrowthemtosuccess.

WHFiswell-posi+onedtodeliverasuperiorannualreturnof20%p.a.

1 2 3 4 5

HEALTHCARE: A DYNAMIC SECTOR WITH ATTRACTIVE GROWTH OPPORTUNITIES

Globalhealthcarespending$9.3trillion

(projected2018)

$2.2trillionInASIA

RiseofAsia

Asiaisnowthemostexci+ngpartoftheworldforhealthcarebusinesseswithageingdemographicsandrapidlyrisingincomesacrosstheregion.

AffluentLifestyle

AffluenceinAsiahasledtosurgeinchronicailmentslikediabetesandcoronarydiseasesandgrowingdemandforhealthcare,includingpreven+veandwell-beinghealthcare.

HealthcareReform

DrivenneedtocontrolhealthcarecostandtoprovidebeMercoverage,thehealthcaresystemisalsoundergoingradicalreformswhichprovideabundantopportuni+esforinnova+vefirms.

WideSpectrum

Healthcareoffersrangeofinvestmentsfromdefensivematurecashgenera+ngassets(clinicchains&establishedpharmacies)toaggressivetargetssuchassmallcapbiotechordrugdiscoverycompaniesthatpoten+allyoffermul+plierreturns.

Cross-BorderInterest

Asianhealthcarecompaniesaregainingconfidenceandhaveincreasinglyseektoexpandacrosstheregiontobuildscaleandwidenscopeofopera+ons.

Globalhealthcarespendingexpectedtoaccelerateataveragerateof5%growthp.ato$9.3trillion*in2018,approx24%($2.2trillion)fromAsia*Worldindustryoutlook:Healthcareandpharmaceu+cals,TheEconomistIntelligenceUnit,May2014

INVESTMENT STRATEGY A BALANCED PORTFOLIO

R&D Sector,

[VALUE] Medical Services Sector,

[VALUE]

Approximately 40% of capital to be deployed inmedical technologies, bioscience and research anddevelopment intensive companies (R&D Sector)includingthefollowingsub-sectors: Drugdevelopment Innova+vemedicaldevicesandequipment HealthcaresupplementsandnaturalremediesApproximately 60% of capital to be deployed inconsumer-centricmedical services sectors (MedicalServicesSector)includingthefollowingsub-sectors: Pharmaceu+calproduc+onanddistribu+on Hospital&clinicsandpharmacychains Healthcare services that support the healthcaresystem

INVESTMENT PROCESS

RiskFocus

Superiorrisk-adjustedconsistentreturnsof20%p.a.withstrongemphasisonriskratherthansimplycap+vatedbyhugepoten+alreturns.

ValueInves6ng

WHFfocusesoncompaniesthatpossessstrongmanagementandsoundbusinessmodelandseekstoaddvaluethroughfinancialdiscipline,opera+onalandstrategicguidance.

Co-investment

Co-optcredibleco-investorsforvalida+on,riskmi+ga+on&accesstoalargerresourcebasetosupportthegrowthofinvesteecompanies.

Diversifica6on

Diversifica+onofriskbynotinves+ngofmorethan15%oftotalfundinanyproject.

Cross-BorderArbitrage

Undertakecrossborderinvestmentstotakeadvantageofvalua+onarbitrageandtoencourageinvesteecompaniestocapturescaleandscopeeconomiesandbestprac+cesknow-how.

PorTolioSynergy

PorTolioobjec+veistobuildaporTolioofcompaniesthathavesynergyamongthemselvesandcontributetothesuccessofthewhole.

CORE COMPETENCIES

CapitalMarket

Experience

ChinaConnec6on

DomainKnowledge

LeongMunWaiOver30yearsofinvestmentbankingexperience: Instrumentalinthesuccessfulini6alpublicofferings(IPOs)ofover100companiesinSGX,HKSEandotherAsianbourses.

ManagingDirectorofaleadingSingaporestockbrokingcompany.

Fundmanagementexperiencewithasovereignwealthfund.

Ma6ldaTanOver30yearsofinvestmentbankingexperience Heldseniorbankingposi6onwithNMRothschild&Sons(Spore&Jakarta).

BoardandInvestmentcommibeememberofAventures1Fundfocusingprimarilyonhealthcareindustry.

HeLiMinPresidentofZhejiangZonebannerJiuzhouGroup,aconglomerateinChinawithbusinessesinpharmaceu6cals,tradi6onalChinesemedicines,chemicals,logis6csandproperty.ZonebanneriscontrollingshareholderofaShanghai-listedpharmaceu6calcompany.HeisinstrumentalinpullinginapanelofmedicalexpertstoprovidespecialistadvicetotheFund.

SimonSunOver40yearsofexperienceinthepetrochemical,chemicalandpharmaceu6calindustry.Heldseniorexecu6veposi6onsinglobalchemicalcompaniesintheUS,EuropeandJapan.

DrHwangChiLooiOver40yearsofR&D,managementandconsul6ngexperienceinglobalpharmaceu6calcompaniesandtheirChinesejointventures.SeniorRegulatoryScien6stoftheSingaporesHealthScienceAuthority.

DrGuZiQiangOver25yearsworkingexperiencesinpharmaceu6calindustry,including15yearswithUSFDAregula6ons,guidance,proceduresintheareaofChemistry,ManufacturingandControls(CMC)andCurrentGoodManufacturingPrac6ce(CGMP).

INVESTMENT STRATEGY + CORE COMPETENCIES SUPERIOR RETURNS

BeberInvesteeQuality

StrongerBargainingPower

CapitalMarketsExperience

DomainKnowledge

ChinaConnec6on

BiggerExpertNetwork

SUPERIORRETURNS

CONFIRMED DEAL PIPELINE

DrugforPeriodon66s

TheinvesteeisaUKbasedandthemanagementteam comprised of ex-senior execu+ves fromNovar+sPharmaceu+cals.

Reposi+oningofanexis+ngdrugcompoundfortreatment of a prevalent dental disease andpreventtoothloss.

Es+mated market size to be about USD2bncurrently but growing because of ageingpopula+on and greater awareness of gooddentalhealth.

Exit through sale to large pharma alercomple+onofphase2trialsintwoyears.

Expectedannualreturnisover30%p.a.

CONFIRMED DEAL PIPELINE

ClinicChain Opera+ngaSingaporebasedclinicchain in

medi-aesthe+cs, dental, ophthalmology,wellnessandspecialistclinics.

Group is currently profitable with posi+vecashflowofSGD6million.

Strategyistoforbrandbuildingandgrowththrough regional expansion and Chinapartnerships

PlantoRTOintoaSGXlistedcointhenext12-24months to poten+ally yield50%+returnp.a. thusproviding liquidityandexitpossibili+es.

FUND TERMSHEET

Type Pan-AsiaPharmaceu6cal&HealthcareFundTargetReturn Morethan20%p.aLaunchDate 30June2016Denomina+on UnitedStatesDollar(USD)Domicile SingaporeTargetFundSize USD100millionPre-ClosingDate 30June2016FirstClosingDate 29September2016FinalClosingDate 29June2017MinimumInvestment USD500,000(USDollarFiveHundredThousand)ManagementFee 2%p.a.oncommiMedcapitalPerformanceFee 20%carriedinterestIni+alDrawdown 40%ofcommiMedcapitalInterest 8%p.aoncommiMedcapitalalerfirstclosingdateFundLife 5yrs+2yrsfromfirstclosingdate

Thank You!